Stadxicam 7.5

Stadxicam 7.5 contains meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti-inflammatory, analgesic and antipyretic properties.

Pack size Box of 50 tablets. Bottle of 30 tablets, 100 tablets
Shelf-life 36 months
Composition Meloxicam
Dosage forms and strengths Tablet: 7.5 mg
Product code :



  • The management of rheumatoid arthritis, for the short-term symptomatic treatment of acute exacerbations of osteoarthritis, and for the symptomatic treatment of ankylosing spondylitis.
  • Treatment of juvenile idiopathic arthritis.


  • Rheumatoid arthritis and ankylosing spondylitis: 15 mg daily as a single dose or 7.5 mg daily (initial dose in patients with an increased risk of adverse reactions or for long-term treatment in the elderly).
  • Acute exacerbations of osteoarthritis: 5 mg daily, increased if necessary to a maximum of 15 mg daily as a single dose.
  • Juvenile idiopathic arthritis in children aged 2 years and over: 125 micrograms/kg once daily, up to a maximum of 7.5 mg daily. According to body-weight, in those aged 12 to 18 years who are intolerant of other NSAIDs: 7.5 mg once daily (less than 50 kg); 15 mg once daily (50 kg and over).
  • Renal impairment: Contraindicated in patients with severe renal impairment. However, in dialysed patients, meloxicam may be given in a oral dose of 7.5 mg daily.


Stadxicam 7.5 is orally administered.

  • Known hypersensitivity to meloxicam or to any of the ingredients.
  • History of urticaria, angioedema, bronchospasm, severe rhinitis, or shock precipitated by aspirin or other NSAIDs.
  • History of aspirin sensitivity, asthma, and nasal polyps.
  • Severely impaired liver function.
  • Non-dialysed severe renal failure.
  • Gastrointestinal bleeding, history of cerebrovascular bleeding.
  • Very common: Dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea.
  • Common: Headache.
  • Treatment with Stadxicam 7.5 should be at the lowest effective daily dose for the shortest duration possible.
  • Risk of cardiovascular thrombotic events: Assess periodically appearance of cardiovascular adverse events, even in the absence of previous cardiovascular symptoms.
  • GI effects: History of GI bleeding or ulceration, longer duration of NSAIDs therapy, treatment with anticoagulants or oral corticosteroids, smoking, alcohol dependence, poor general health, or older age may increase risk of fatal GI complications.
  • Hypertension: Meloxicam can result in the onset of hypertension or worsening of preexisting hypertension, may contribute to the increased incidence of cardiovascular events.
  • Renal effects: Renal papillary necrosis or other renal medullary changes may occur with long-term administration of NSAIDs.
  • Sensitivity reactions: Possible in patients without prior exposure to meloxicam. Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) can occur.
  • Hematologic effects: Anemia, principally in patients receiving long-term (6 months’ duration) therapy with meloxicam.
  • Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take Stadxicam 7.5.
  • Avoid use Stadxicam 7.5 in the third trimester. Meloxicam is distributed into milk in rats; discontinue nursing or drug because of potential risk in nursing infants.
  • Patients should be aware of how they react to Stadxicam 7.5 before driving or operating machinery.